Utah Medical Products, Inc. (UTMD) Stock Price & Analysis
Utah Medical Products, Inc. (UTMD) closed at USD 74.23 on Friday, October 23, 2026, down 1.11% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 75.06; the Oct 23, 2026 session ranged USD 74.04–75.13 on volume of 38,388 shares. Market capitalization is $235.68M, with a 52-week range of USD 53.66–76.89 (NMS). Source: Nexqual, retrieved October 24, 2026 at 03:48 UTC.
Also available as compact Markdown for AI agents: nexqual.com/UTMD.md
Key facts (UTMD)
- Last four reported quarters (through Jun 30, 2026): revenue $36.1M, net income $10.5M (29.0% margin), free cash flow $11.4M (SEC filings).
- Valuation: P/E 22.5x (avg 16.7x at the last 3 fiscal year-ends), EV/EBITDA 13.4x, net cash $87.3M.
- Analysts: None.
- Total return with dividends: 1Y +25.2% vs S&P 500 +13.4%; 5Y -15.5% vs S&P 500 +76.9%.
- Next earnings: 2026-10-22, EPS estimate USD —, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (UTMD)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $49.1M | $52.3M | $50.2M | $40.9M | $38.5M | $36.1M |
| Gross profit | $30.9M | $32.2M | $30.0M | $24.1M | $22.0M | — |
| Operating income | $18.9M | $19.8M | $16.8M | $13.6M | $11.4M | $10.3M |
| Net income | $14.8M | $16.5M | $16.6M | $13.9M | $11.3M | $10.5M |
| EPS (diluted) | $4.04 | $4.52 | $4.57 | $3.96 | $3.48 | — |
| Free cash flow | $20.7M | $20.3M | $21.6M | $14.6M | $14.3M | $11.4M |
| Gross margin | 63.0% | 61.6% | 59.8% | 59.0% | 57.1% | — |
| Operating margin | 38.5% | 37.9% | 33.4% | 33.2% | 29.6% | 28.4% |
| Net margin | 30.1% | 31.5% | 33.1% | 33.9% | 29.3% | 29.0% |
| Revenue growth | +16.3% | +6.6% | -3.9% | -18.6% | -5.8% | — |
| Cash + short-term investments | $61.0M | $75.1M | $92.9M | $83.0M | $85.8M | — |
| Total debt | $0K | $0K | $0K | $0K | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (UTMD)
P/E 22.5x · P/S 6.5x · EV/EBITDA 13.4x · EV/Sales 4.1x · P/FCF 20.6x · P/B 1.9x · FCF yield 4.86% · Earnings yield 4.45% · Dividend yield (paid, TTM) 1.67% · Buyback yield (TTM) 0.79% · Net cash $87.3M · EV $148M
P/E at fiscal year-ends: Dec 2025 16.1x, Dec 2024 15.5x, Dec 2023 18.4x.
Analysts (UTMD)
Consensus None.
Total return (dividends reinvested) (UTMD)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +25.2% | -15.5% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +25.3% | -3.3% |
| Volatility (annualized) | 27.8% | 25.1% |
| Max drawdown | -13.2% (Jun 2026→Jul 2026) | -53.5% (Nov 2021→Apr 2025) |
UTMD revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Gynecology Electrosurgery Urology | $4.3M | 50.2% | -11.0% |
| Neonatal | $1.9M | 22.5% | -8.7% |
| Blood Pressure Monitoring & Accessories | $1.3M | 14.8% | -37.4% |
| Obstetrics | $1.1M | 12.5% | +4.0% |
| Total revenue | $8.5M | 100% | — |
UTMD revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Domestic Us | $5.2M | 60.6% | -11.9% |
| Outside Us | $3.4M | 39.4% | -17.7% |
| Total revenue | $8.5M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
UTMD company outlook (results filed Oct 22, 2026)
- “However, the 2026 growth in new biopharm sales has been slower than expected.”
- “In 4Q 2025 and 4Q 2024, the two former customers with zero combined sales in 2026 were just $35 and $338, so UTMD does not expect the same negative comparisons with the past in 4Q 2026.”
- “Looking forward, UTMD expects the combined 4Q 2026 replacement sales to be higher than in both former 4Q periods.”
- “Although sales to other biopharma OEM customers in 2026 have not developed as soon as projected at the beginning of the year, finding a replacement China distributor for BPM kits and the acquisition of Orion Medical was also not projected.”
Quoted word-for-word from the SEC 8-K results press release.
UTMD analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2017) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 03:48 UTC)
| Price | USD 74.23 |
|---|---|
| Change | ▼ 1.11% (down) |
| Previous Close | USD 75.06 |
| Open | USD 75.13 |
| Day Range | USD 74.04 – 75.13 |
| 52-Week Range | USD 53.66 – 76.89 |
| Volume | 38,388 shares |
| Market Cap | $235.68M |
| Exchange | NMS |
Technical Analysis (UTMD)
Nexqual's technical model rates UTMD "NEUTRAL" based on 3 bullish and 2 bearish signals across 127 daily candles, as of October 24, 2026 at 03:48 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 57.12 (neutral) |
| vs SMA50 | Above (USD 73.03) |
| MACD | 0.45 (positive) |
Analyst Ratings (UTMD)
Wall Street analysts rate UTMD "None", per Nexqual as of October 24, 2026 at 03:48 UTC.
| Consensus Rating | None |
|---|
Earnings (UTMD)
| Next Earnings Date | 2026-10-22 |
|---|
Source: Nexqual, October 24, 2026 at 03:48 UTC.
Financials & Fundamentals (UTMD)
| Total Revenue | $36.11M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -14.30% |
| Gross Margin | +57.90% |
| Operating Margin | +36.89% |
| Profit Margin | +29.04% |
| ROE | +8.76% |
| Debt / Equity | 0 |
| Current Ratio | 48.62 |
| Total Cash | $87.53M |
| Total Debt | $195,000 |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $11.45M (31.7% of revenue) |
Source: Nexqual, October 24, 2026 at 03:48 UTC.
Financial Health Score (UTMD)
Nexqual rates Utah Medical Products, Inc.'s overall financial health "Mixed" across five dimensions, as of October 24, 2026 at 03:48 UTC.
| Growth | Critical — Revenue -14% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Strong — $88M cash and investments, no debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $11M (last 4 quarters to Jun 2026, SEC), 32% margin |
| Efficiency | Mixed — ROE 9%, ROA 6.1% |
Ownership (UTMD)
| Insider Ownership | +7.18% |
|---|---|
| Institutional Ownership | +76.68% |
| Shares Outstanding | 3.18M |
| Float | 2.78M |
| Short % of Float | +5.86% |
Source: Nexqual, October 24, 2026 at 03:48 UTC.
Leadership (UTMD)
Utah Medical Products, Inc. is led by Kevin L. Cornwell, Chairman, CEO, President & Secretary, per Nexqual as of October 24, 2026 at 03:48 UTC.
| Chairman, CEO, President & Secretary | Kevin L. Cornwell |
|---|---|
| Vice President of Marketing | Mark L. Fox |
| Vice President of Corporate Sales | Marcena H. Clawson |
Major Backers & Investors (UTMD)
Notable institutional backers of Utah Medical Products, Inc. include Brandes Investment Partners L.P., Renaissance Technologies, Minerva Advisors LLC, according to Nexqual as of October 24, 2026 at 03:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Brandes Investment Partners L.P. | 14.92% |
| Renaissance Technologies | 5.52% |
| Minerva Advisors LLC | 2.94% |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Value Portfolio | 2.78% |
| Hotchkis & Wiley Capital Management, LLC | 2.68% |
| Rice, Hall, James & Associates LLC | 2.24% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.4% |
| Dimensional Fund Advisors | 6.24% |
| Vanguard Group | 4.23% |
| Geode Capital | 3.39% |
Source: Nexqual, October 24, 2026 at 03:48 UTC.
From Utah Medical Products, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- UTMD's bell-shaped soft silicone TENDER TOUCH® cups yield fewer complications compared to other vacuum cup designs, as evidenced by the FDA Medical Device Reporting System (MAUDE) which publicly lists serious injuries reported by hospitals using specific brand names of products.
- Recognizing the important need to prevent misadministration of enteral feeding or medication by the wrong route, the FDA in February 2015 released its guidance, "Safety Considerations to Mitigate the Risks of Misconnections with Small Bore Connectors Intended for Enteral Applications." The guidance includes compliance with ISO 80369-3 standard connectors.
- As mandated by the FDA, Femcare (the developer and manufacturer of the Filshie Clip System) is required to submit an annual experience report for FDA's continual review and vigilance of the safety and effectiveness of the PMA device.
Legal & Regulatory Risks (Item 1A, quoted)
- Regulatory burdens may result in significant loss of revenue, unpredictable costs and loss of management focus on developing and marketing products that improve the quality of healthcare.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KMTS | Kestra Medical Technologies, Lt | USD 28.76 | ▲ 1.55% |
| XRAY | DENTSPLY SIRONA Inc. | USD 9.43 | ▼ 0.74% |
| LMAT | LeMaitre Vascular, Inc. | USD 84.45 | ▼ 1.03% |
| ATRC | AtriCure, Inc. | USD 58.97 | ▼ 0.56% |
| WRBY | Warby Parker Inc. | USD 25.91 | ▲ 0.93% |
| PLSE | Pulse Biosciences, Inc | USD 53.02 | ▲ 0.65% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 03:48 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt